Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E2F1-induced apoptosis: turning killers into therapeutics.

Jens Stanelle1, Brigitte M Pützer

  • 1Department of Vectorology and Experimental Gene Therapy, University of Rostock, Schillingallee 70, 18057 Rostock, Germany.

Trends in Molecular Medicine
|March 15, 2006
PubMed
Summary

The transcription factor E2F1 acts as a tumor suppressor by initiating programmed cell death (apoptosis). Recent research explores E2F1

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.

Biomarker research·2026
Same author

Integrative Multimodal Profiling of TAp73 and DNp73 Reveals Isoform-Specific Transcriptomic Coregulator Landscapes in Cancer Programs.

Biomolecules·2026
Same author

TAp73α drives cancer metastasis via PPI-mediated derepression of the neuronal HDAC2/REST-GABBR2 axis.

Cancer letters·2025
Same author

CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy.

Biomedicines·2025
Same author

E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune crosstalk that predicts T cell phenotype switching and therapeutic responsiveness.

Frontiers in immunology·2024
Same author

Novel Viral Vectors for Gene Therapy.

Viruses·2024

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Death Pathways

Background:

  • The cellular transcription factor E2F1 is a key component of the anti-tumorigenic safeguard mechanism.
  • E2F1 initiates programmed cell death (apoptosis) pathways, either independently or in conjunction with p53, to prevent tumor development.
  • E2F1 activation leads to downstream gene expression changes that trigger apoptosis, though precise mechanisms require further elucidation.

Purpose of the Study:

  • To review and highlight recent findings on E2F1's role in apoptosis across different cellular contexts.
  • To examine the therapeutic potential of E2F1 and its associated apoptotic pathways as drug targets.
  • To provide insights into the fundamental mechanisms of E2F1-induced apoptosis and its clinical relevance.

Main Methods:

  • Review of existing literature on E2F1 and apoptosis.
  • Analysis of recent follow-up studies investigating E2F1's role in various cellular backgrounds.
  • Exploration of therapeutic strategies targeting E2F1-induced apoptotic pathways.

Main Results:

  • E2F1 demonstrates diverse roles in programmed cell death, contingent upon the cellular environment.
  • Emerging studies utilize apoptotic E2F1 genes as novel therapeutic agents or drug targets.
  • Significant progress has been made in understanding the basic mechanisms of E2F1-mediated apoptosis.

Conclusions:

  • E2F1 is a critical regulator of apoptosis and a crucial factor in tumor suppression.
  • The therapeutic targeting of E2F1-induced apoptosis holds promise for cancer treatment.
  • Further research into E2F1's mechanisms can illuminate its clinical implications in oncology.

Related Experiment Videos